Please ensure Javascript is enabled for purposes of website accessibility

Why Adamas Pharmaceuticals Fell Today

By Brian Orelli, PhD - Updated Feb 20, 2018 at 2:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Potential competition has investors spooked.

What happened

Adamas Pharmaceuticals (ADMS) is down 20.7% at 12:57 p.m. EST after the Food and Drug Administration approved Osmotica Pharmaceutical and Vertical Pharmaceuticals' Osmolex ER, a potential rival to Adamas' Gocovri.

So what

Osmolex ER and Gocovri contain the same active ingredient, amantadine, which already has generic options on the market. Both Adamas and Osmotica/Vertical improved the drug by developing extended-release versions of amantadine.

That's where the similarities end.

Adamas tested Gocovri in patients with Parkinson's disease who have uncontrolled involuntary movements, called dyskinesia, often caused by treatment with another Parkinson's disease drug, levodopa. In clinical trials, Gocovri increased the amount of time patients didn't have dyskinesia symptoms compared to the placebo group.

Osmotica and Vertical got Osmolex ER approved under the FDA's 505(b)(2) pathway, which allows drugmakers to use the efficacy data from previous clinical trials and only test the bioavailability of their drug. For Osmolex ER, Osmotica and Vertical tested the bioavailability of the drug compared to immediate-release amantadine syrup in healthy volunteers.

A closeup of the definition of Parkinson's disease on a page

Image source: Getty Images.

The different approval pathways result in different labels. Gocovri is approved for "treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy" based on its clinical trials, while Osmolex ER is approved for the "treatment of Parkinson's disease and for the treatment of drug-induced extrapyramidal reactions [drug-induced movement disorders]" based on clinical trials of the previously approved immediate-release drugs.

On Friday, Osmotica and Vertical took a pre-emptive strike, filing an action in federal court asking for a declaratory judgment that Osmolex ER doesn't infringe on Adamas' patents covering compositions and uses of amantadine.

Now what

The best-case scenario for Adamas would be that a judge finds that Osmolex ER infringes on Adamas' patents and rules that Osmolex ER has to be pulled off the market. Unfortunately, it's really hard for investors to handicap the likelihood of a positive outcome from the lawsuit.

If it stays on the market, how much Osmolex ER will interfere with Gocovri's sales is also a bit of a mystery. Doctors are free to prescribe Osmolex ER "off-label" specifically to treat dyskinesia in patients with Parkinson's disease; they've been doing it with immediate-release amantadine for years. Of course, Adamas will argue it's the only one with data that shows its version of amantadine helps dyskinesia, which should convince some doctors to use Gocovri even if it's a more expensive option.

Adamas Pharmaceuticals will report fourth-quarter earnings on Thursday. The report will offer a first look at how sales of Gocovri are going and presumably some color from management on its strategy with the new competition.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adamas Pharmaceuticals, Inc. Stock Quote
Adamas Pharmaceuticals, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.